What does this research mean for the field?

Treatment with interferon-α2b significantly reduces the duration of detectable SARS-CoV-2 in the upper respiratory tract and shortens the duration of elevated inflammatory markers such as IL-6 and CRP in hospitalized COVID-19 patients. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 15, 2020Frontiers in ImmunologyOpen Access

Interferon-α2b Treatment for COVID-19

View Full Paper

Ask AI

Bookmark

Authors

QZQiong ZhouUnion Hospital VCVirginia ChenPrevention of Organ Failure CSCasey P. ShannonBoston Children's Hospital

Discussion

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhou et al. (2020) studied this question.

synapsesocial.com/papers/6aa95b3215a756b5ce463a64 https://doi.org/10.3389/fimmu.2020.01061

View Full Paper

Ask AI

Bookmark

May 15, 2020Frontiers in ImmunologyOpen Access

Interferon-α2b Treatment for COVID-19

View Full Paper

Ask AI

Bookmark

Authors

QZQiong ZhouUnion Hospital VCVirginia ChenPrevention of Organ Failure CSCasey P. ShannonBoston Children's Hospital

Discussion

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhou et al. (2020) studied this question.

synapsesocial.com/papers/6aa95b3215a756b5ce463a64 https://doi.org/10.3389/fimmu.2020.01061

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark